Saltar al contenido

Acadia Pharmaceuticals Inc (ACAD) stock: revenue, earnings & dividend

Acadia Pharmaceuticals Inc (ACAD, Nasdaq): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener ACAD · Nasdaq Pharma & Biotech US-CA

Key figures

Fiscal year
2025
Revenue
1.07 bn $
Revenue growth
11.9 %
Revenue growth 5y (p.a.)
19.4 %
Net income
391 m $
Net margin
36.5 %
Operating margin
9.8 %
Earnings per share (diluted)
2.30 $
Dividend per share
–
Payout ratio
–
Consecutive dividend years
–
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
1.56 bn $
Equity
1.23 bn $
Equity ratio
78.5 %
Return on equity
31.9 %
Cash
178 m $
Operating cash flow
110 m $
Free cash flow
105 m $
Shares outstanding
172,828,972

History

Revenue by fiscal year

2016 17.3 m $
2017 125 m $
2018 224 m $
2019 339 m $
2020 442 m $
2021 484 m $
2022 517 m $
2023 726 m $
2024 958 m $
2025 1.07 bn $

Net income by fiscal year

2016 -271.39 m $
2017 -289.4 m $
2018 -245.19 m $
2019 -235.26 m $
2020 -281.58 m $
2021 -168 m $
2022 -214 m $
2023 -61 m $
2024 226 m $
2025 391 m $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
20251.07 bn $391 m $2.30 $–110 m $
2024958 m $226 m $1.36 $–158 m $
2023726 m $-61 m $-0.37 $–16.7 m $
2022517 m $-214 m $-1.34 $–-114.04 m $
2021484 m $-168 m $-1.05 $–-125.66 m $
2020442 m $-281.58 m $-1.79 $–-136.17 m $
2019339 m $-235.26 m $––-151.13 m $
2018224 m $-245.19 m $––-167.47 m $
2017125 m $-289.4 m $––-217.76 m $
201617.3 m $-271.39 m $––-208.41 m $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)